David Morris

1.2k total citations
25 papers, 224 citations indexed

About

David Morris is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, David Morris has authored 25 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Surgery. Recurrent topics in David Morris's work include Prostate Cancer Treatment and Research (12 papers), PARP inhibition in cancer therapy (8 papers) and Bladder and Urothelial Cancer Treatments (6 papers). David Morris is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), PARP inhibition in cancer therapy (8 papers) and Bladder and Urothelial Cancer Treatments (6 papers). David Morris collaborates with scholars based in United States, United Kingdom and Spain. David Morris's co-authors include Veda N. Giri, Colette Hyatt, Dudley H. Williams, Todd M. Morgan, Mary‐Ellen Taplin, Jacob E. Berchuck, Neal D. Shore, Charles J. Ryan, Sophie Callies and Alan H. Bryce and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

David Morris

24 papers receiving 219 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Morris United States 8 102 68 65 64 39 25 224
Anishka D'souza United States 6 95 0.9× 87 1.3× 57 0.9× 66 1.0× 55 1.4× 25 201
Carmen Mir Spain 7 107 1.0× 70 1.0× 121 1.9× 93 1.5× 29 0.7× 13 264
Jordan Kardos United States 7 78 0.8× 80 1.2× 129 2.0× 111 1.7× 51 1.3× 11 254
Xingbo Long China 9 115 1.1× 102 1.5× 86 1.3× 134 2.1× 63 1.6× 30 302
Zhiqun Shang China 6 67 0.7× 37 0.5× 60 0.9× 155 2.4× 119 3.1× 8 282
Juan Francisco Rodríguez-Moreno Spain 9 71 0.7× 86 1.3× 59 0.9× 74 1.2× 50 1.3× 37 192
Alex Freeman United Kingdom 6 48 0.5× 81 1.2× 43 0.7× 105 1.6× 45 1.2× 10 226
J. Samuel United Kingdom 5 73 0.7× 110 1.6× 52 0.8× 81 1.3× 29 0.7× 8 205
Gopa Iyer United States 9 47 0.5× 103 1.5× 149 2.3× 112 1.8× 36 0.9× 52 299
Victoria Hinder New Zealand 7 64 0.6× 109 1.6× 136 2.1× 67 1.0× 26 0.7× 18 264

Countries citing papers authored by David Morris

Since Specialization
Citations

This map shows the geographic impact of David Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Morris more than expected).

Fields of papers citing papers by David Morris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Morris. The network helps show where David Morris may publish in the future.

Co-authorship network of co-authors of David Morris

This figure shows the co-authorship network connecting the top 25 collaborators of David Morris. A scholar is included among the top collaborators of David Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Morris. David Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morris, David, et al.. (2025). HOME INSTILLATION OF UGN-102 FOR PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE 3B TRIAL. Urologic Oncology Seminars and Original Investigations. 43(3). 50–50. 1 indexed citations
2.
Bryce, Alan H., Ray McDermott, Josep M. Piulats, et al.. (2025). Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.. Journal of Clinical Oncology. 43(5_suppl). 155–155. 3 indexed citations
3.
4.
Jacob, Joseph M, Siamak Daneshmand, Giuseppe Simone, et al.. (2023). LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy. Annals of Oncology. 34. S1343–S1344. 10 indexed citations
5.
Tyson, Mark D., David Morris, Juan Palou, et al.. (2023). Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. The Journal of Urology. 209(5). 890–900. 22 indexed citations
6.
Labadie, Brian, David Morris, Alan H. Bryce, et al.. (2022). Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. SHILAP Revista de lepidopterología. 4 indexed citations
7.
Sweeney, Christopher J., Ivor Percent, Sunil Babu, et al.. (2022). Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(11). 2237–2247. 31 indexed citations
8.
Morris, David, et al.. (2022). Prehospital decompression of tension pneumothorax: Have we moved the needle?. The American Journal of Surgery. 224(6). 1460–1463. 1 indexed citations
9.
Giri, Veda N., Todd M. Morgan, David Morris, et al.. (2022). Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal for Clinicians. 72(4). 360–371. 30 indexed citations
10.
Khojah, Amer, Soma Jyonouchi, Yasmin Khan, et al.. (2021). TREC Screening for WHIM Syndrome. Journal of Clinical Immunology. 41(3). 621–628. 5 indexed citations
11.
Santos, Ariel, David Morris, Rishi Rattan, & Tanya L. Zakrison. (2021). Double-blinded manuscript review: Avoiding peer review bias. The Journal of Trauma: Injury, Infection, and Critical Care. 91(1). e39–e42. 4 indexed citations
12.
Seelaus, Rosemary, et al.. (2021). State of the Art Care in Computer-Assisted Facial Prosthetic Rehabilitation. Journal of Craniofacial Surgery. 32(3). 1255–1263. 6 indexed citations
13.
Shore, Neal D., David Cahn, Christopher Pieczonka, et al.. (2021). PD13-10 UNIVERSAL GERMLINE TESTING OF PROSTATE CANCER PATIENTS: ARE GENETIC TESTING GUIDELINES AN IMPEDIMENT TO PRECISION THERAPY?. The Journal of Urology. 206(Supplement 3). 1 indexed citations
14.
Fizazi, Karim, Neal D. Shore, Matthew Smith, et al.. (2021). Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. Journal of Clinical Oncology. 39(15_suppl). 5079–5079. 4 indexed citations
15.
Hardwick, Mary Kay, Edward D. Esplin, David Morris, et al.. (2021). 628P Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?. Annals of Oncology. 32. S663–S663. 1 indexed citations
16.
Morris, David, James S. Woods, Jennifer Logan, et al.. (2020). Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer. Urologic Oncology Seminars and Original Investigations. 39(6). 366.e19–366.e28. 4 indexed citations
17.
Sweeney, Christopher J., Ivor Percent, Sunil Babu, et al.. (2019). Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.. Journal of Clinical Oncology. 37(15_suppl). 5009–5009. 9 indexed citations
18.
19.
Barocas, Daniel A., Alice Liu, Frank Burks, et al.. (2013). Practice Based Collaboration to Improve the Use of Immediate Intravesical Therapy after Resection of Nonmuscle Invasive Bladder Cancer. The Journal of Urology. 190(6). 2011–2016. 26 indexed citations
20.
Morris, David, et al.. (1981). Structure and synthesis of 25-hydroxycholecalciferol-26,23-lactone, a metabolite of vitamin D. The Journal of Organic Chemistry. 46(17). 3422–3428. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anishka D'souza Breakdown of academic impact, for papers by Carmen Mir Breakdown of academic impact, for papers by Jordan Kardos Breakdown of academic impact, for papers by Xingbo Long Breakdown of academic impact, for papers by Zhiqun Shang Breakdown of academic impact, for papers by Juan Francisco Rodríguez-Moreno Breakdown of academic impact, for papers by Alex Freeman Breakdown of academic impact, for papers by J. Samuel Breakdown of academic impact, for papers by Gopa Iyer Breakdown of academic impact, for papers by Victoria Hinder
Rankless by CCL
2026